Aktienanalyse zu Azitra Inc (AZTR)AZTRAzitra Inc

Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live bio therapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, chronic, xerotic (abnormally dry), and scaly skin disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Azitra Inc is not a good buy right now due to its significant financial losses and poor performance metrics. The current price is $0.75, which is 81.24% lower than its 1-year high of $4.30. Additionally, the company has a negative forward P/E ratio and a gross margin of 0%, indicating ongoing financial struggles. The RSI is at 35.238, suggesting the stock is oversold, but the overall trend remains negative with a 20-day change of -42.42%.